Montalban, Xavier et al "Rationale and Design of two Phase 3 Randomized Controlled Trials (Evolution RMS 1&2) Evaluating the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib in Patients with Relapsing Multiple Sclerosis (4071)." Neurology 94.15 Supplement (2020): 4071. Web. 17 May. 2022.